Anzeige
Mehr »
Login
Samstag, 11.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
100 % Anstieg in zwei Tagen: Das technische Signal, das Wall Streets Bären in Panik versetzt!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
332 Leser
Artikel bewerten:
(1)

Sceptre Ventures Inc.: Sceptre Ventures Announces Closing of Shares for Debt Transaction

Finanznachrichten News

VANCOUVER, BC / ACCESSWIRE / July 27, 2022 / Sceptre Ventures Inc. ("Sceptre" and/or the "Company") (TSXV:SVP.H)(NEX:SVP.H) announces that it has agreed to issue an aggregate of 6,806,192 common shares (each, a "Share") at a deemed price of $0.06 per Share to certain directors and officers of the Company (the "Insiders") and certain consultants of the Company as full and final payment of debt in the aggregate amount of $408,371.58 (the "Debt Settlement"), to settle certain amounts owed by the Company for unpaid consulting services.

Accordingly, the portion of the Debt Settlement with the Insiders constituted a "related party transaction" within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The issuance of the Shares to the Insiders was exempt from the valuation requirement of MI 61-101 by the virtue of the exemption contained in section 5.5(b) as the Company's Shares are not listed on a specified market and from the minority shareholder approval requirements of MI 61-101 by virtue of the exemption contained in Section 5.7(1)(a) as the value of the Shares issued under the Debt Settlement did not exceed 25% of the Company's market capitalization.

By reason of the Debt Settlement, Zimtu Capital Corp. ("Zimtu") acquired 4,302,626 Shares, which represents approximately 35.83% of the total issued and outstanding common shares of the Company. The Company is informed that Zimtu, and all persons acting jointly or in concert with it, did not hold any Shares prior to the Debt Settlement. Zimtu intends to hold the Shares for investment purposes. Depending upon market conditions and other factors, it may from time to time acquire additional securities of the Company, dispose of some or all of the existing or additional securities it holds in the Company, or will hold or may continue to hold its current position.

Additional information concerning the foregoing will be contained in the Early Warning Report to be filed by Zimtu on SEDAR under the Company's profile.

All securities issued in connection with the Debt Settlement will be subject to a statutory hold period expiring four months and one day after the date of issuance (the "Issuance Date"), as set out in National Instrument 45-102 - Resale of Securities.

The Debt Settlement has been approved by the TSX Venture Exchange and, in the case of Zimtu, has been approved by disinterested shareholders of the Company because the issuance of the Shares caused it to become a "control person" as that term is defined under applicable securities laws.

About Sceptre Ventures Inc.

Sceptre Ventures Inc. is a Capital Pool Company ("CPC") within the meaning of the policies of the TSX Venture Exchange and has not commenced commercial operations and has no assets other than cash. Sceptre is currently engaged in identifying and evaluating businesses and assets with a view to completing a Qualifying Transaction under the TSXV's CPC policy.

For Further Information:
Suite 1450-789 West Pender Street
Vancouver, BC, V6C 1H2, Canada
Tel: 604-688-4219
Email: mitchell@sceptreventures.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE: Sceptre Ventures Inc.



View source version on accesswire.com:
https://www.accesswire.com/710024/Sceptre-Ventures-Announces-Closing-of-Shares-for-Debt-Transaction

© 2022 ACCESSWIRE
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.